Loading...
Loading...
Singular Research reiterated its BioSante Pharmaceuticals
BPAX Buy rating and maintained its $7 price target in a research report published today.
In the report, Singular Research states, "The Phase III clinical trials for LibiGel® are completed and the company is compiling the data. Management has announced it will release a data summary in December 2011."
Shares of BioSante Pharmaceuticals were trading at $2.58 at the time of posting, up 1.57% from Monday's market close.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in